Synagis

Generic name: Palivizumab
Drug class: Immune globulins

Usage of Synagis

Synagis is a man-made antibody to respiratory syncytial virus (RSV). RSV can cause serious illness in children. Palivizumab helps keep RSV cells from multiplying in the body.

Synagis is used to prevent serious lung disease caused by respiratory syncytial virus in premature infants, and infants born with certain lung disorders or heart disease.

Synagis works best in children who are 24 months old or younger at the beginning of RSV season (6 months or younger for premature infants). It will not treat a child who is already sick with RSV disease.

Synagis side effects

Get emergency medical help if your child has signs of an allergic reactionto Synagis: hives, severe rash, itching; rapid or difficult breathing; blue-colored lips, skin, or fingernails; muscle weakness, being hard to wake up; swelling of the face, lips, tongue, or throat.

Common Synagis side effects may include:

fever; or

rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Synagis

Synagis should not be given to a child who has had a severe allergic reaction to palivizumab.

To make sure Synagis is safe for your child, tell your doctor if the child has ever had:

a bleeding or blood clotting disorder; or

low levels of platelets in the blood.

Relate drugs

How to use Synagis

Usual Pediatric Dose for Respiratory Syncytial Virus:

Pediatric patients 24 months of age or less: 15 mg/kg IM once a month during RSV season (the first dose should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season) Comments: -Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season. -In the northern hemisphere, the RSV season typically commences in November and lasts through April, but it may begin earlier or persist later in certain communities. -Serum levels of this drug are decreased after cardiopulmonary bypass. Children undergoing cardiopulmonary bypass should receive an additional dose as soon as possible after the cardiopulmonary bypass procedure (even if sooner than a month from the previous dose). Thereafter, doses should be administered monthly as scheduled. Use: For the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. The following points should be considered when prescribing this drug: -Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). -Safety and efficacy have not been established for treatment of RSV disease.

Warnings

Synagis should not be given to a child who has had a severe allergic reaction to palivizumab.

Before your child receives the injection, tell your doctor if the child has a bleeding or blood-clotting disorder; or a low level of platelets in the blood.

Call your doctor at once if your child has a serious side effect after receiving this medicine, such as high fever, ear pain or drainage, warmth or swelling of the ear; crying or fussiness, change in appetite or sleeping patterns, easy bruising or bleeding, or trouble breathing.

What other drugs will affect Synagis

Other drugs may interact with palivizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.